Company profile
Upper Street Marketing Inc.
OTC: UPPR · Healthcare · Medical - Pharmaceuticals
#1120 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH 26DQ —GM —SS 37
v0.1 · 35/100 weight · pillars only
↑ listing tenure, disclosure history · ↓ operating margin, net margin
Methodology →Revenue TTM
$55.2k
Rev growth YoY (TTM)
-70.8%
Net income (FY)
-$1.4M
Employees
3
as of 2026-08-30
Market cap
$8.0k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$15.0k$15.0k2025
Net income-$1.4M-$1.4M2025
Operating income-$1.3M-$1.3M2025
Total assets$3.1M$3.1M2025
Liabilities$2.2M$2.2M2025
Equity$870.2k$870.2k2025
Revenue trend
FY2016 – FY2025 · USD
FY16
FY17
FY18
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Upper Street Marketing Inc.’s revenue?
Upper Street Marketing Inc. booked $15.0k in FY2025 revenue, contracting 92% year over year — slower than 90% of Healthcare companies we track, at a -9294.3% net margin.
Peers · Healthcare
Nanobac Pharmaceuticals, Incorporated——REMSleep Holdings, Inc.19DGemina Laboratories Ltd.——Pineapple, Inc.——Cardio Diagnostics Holdings, Inc.30DNavidea Biopharmaceuticals, Inc.——Neighbors
Maricopa →Key facts
CEOJohn Quinn
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersScottsdale, AZ
ExchangeOTC: UPPR
Employees3
IPO date1998-06-29
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.